Stocks TelegraphStocks Telegraph
Stock Ideas

LNTH Company Profile and Key Details

NASDAQ : LNTH

Lantheus

$64.89
0.03+0.05%
At Close 4:00 PM
74.13
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Lantheus Holdings, Inc. (LNTH) stock surged +0.05%, trading at $64.89 on NASDAQ, up from the previous close of $64.86. The stock opened at $65.51, fluctuating between $64.10 and $65.68 in the recent session.

Stock Snapshot

64.86
Prev. Close
4.41B
Market Cap
64.1
Day Low
26.93
P/E Ratio
2.41
EPS (TTM)
3.78
Cash Flow per Share
65.51
Open
67.99M
Number of Shares
65.68
Day High
92.92%
Free Float in %
11.91
Book Value
826.03K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 06, 202665.5166.0563.8464.89828.05K
Feb 05, 202666.5167.5064.2564.86827.49K
Feb 04, 202666.4367.5365.7765.93720.89K
Feb 03, 202666.6368.6965.2666.00531.85K
Feb 02, 202666.9168.0066.4366.50769.73K
Jan 30, 202666.5067.2665.6366.92658.24K
Jan 29, 202666.3166.8664.8266.68687.5K
Jan 28, 202668.1468.1465.4166.31555.02K
Jan 27, 202667.3768.0466.5967.89536.61K
Jan 26, 202667.5869.2067.1367.81525.8K
Jan 23, 202666.9167.8966.5467.51619.77K
Jan 22, 202666.5967.9265.9767.18627.18K
Jan 21, 202666.2567.0865.1966.44742.01K
Jan 20, 202663.7567.0063.3765.88962.63K
Jan 16, 202665.2265.2564.0864.25707.1K
Jan 15, 202665.2265.9964.6965.42973.15K
Jan 14, 202665.8466.3465.1365.60809.27K
Jan 13, 202667.4467.4464.3465.84879.57K
Jan 12, 202667.5567.6365.2467.48674.4K
Jan 09, 202667.5668.2566.1267.56901.9K

Contact Details

Bedford, MA 01862

United States

https://www.lantheus.com978 671 8001

About Company

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Company Information

Employees808
Beta-0.11
Sales or Revenue$1.30B
5Y Sales Change%1.115%
Fiscal Year EndsDecember
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Stock Peers

NBIX
3.27+2.37%
Neurocrine Biosciences, Inc.$141.20ITCI
00
Intra-Cellular Therapies, Inc.$131.87ANIP
0.34+0.42%
ANI Pharmaceuticals, Inc.$81.84PAHC
3.07+6.14%
Phibro Animal Health Corporation$53.07SUPN
2.28+4.62%
Supernus Pharmaceuticals, Inc.$51.65COLL
0.69+1.47%
Collegium Pharmaceutical, Inc.$47.61HROW
1.26+2.74%
Harrow Health, Inc.$47.32INDV
-0.09-0.26%
Indivior Pharmaceuticals Inc$34.36PETQ
-0.01-0.03%
PetIQ, Inc.$30.98AMPH
0.63+2.20%
Amphastar Pharmaceuticals, Inc.$29.26

Company Overview

Lantheus Holdings, Inc. (NASDAQ:LNTH) closed at $64.89 USD, gaining $0.03 (0.05%) from the previous close of $64.86. The stock is currently mid-range between its 52-week high and low $47.25 and $111.29. With a market capitalization of about $4.41 billion, Lantheus Holdings, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.09). Key stats such as the average daily volume over the past year has been around 999.97 thousand shares, in line with its 52-week average. Headquartered in Bedford, MA, Lantheus Holdings, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Mary Anne Heino, the company employs approximately 808 people and listed since June 25, 2015. Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -2.2%, SMA50 -0.47%, SMA200 -2.85%). The stock’s 14-day RSI is 43.48 (neutral), while the ATR of 2.11 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -41.69% below its high and over 37.33% above its low. Average 10-day trading volume of 679.49 thousand shares is below the 3-month average of 968.45 thousand, indicating normal recent market interest.

Valuation Metrics

Lantheus Holdings, Inc. trades at a P/E ratio of 25.8, slightly below the S&P 500 average, with a price-to-sales ratio of 2.87 and a price-to-book ratio of 3.86 trading at moderately above to book value. The P/FCF stands at 10.77, also above market averages.

Dividend & Fair Value

Lantheus Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $304.28. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Lantheus Holdings, Inc. generated EPS of $2.38 over the past year. Five-year average earnings growth is 40.75%. Wall Street analysts project EPS growth of -3.32% annually over the next five years. The latest quarter delivered EPS of $0.41. The next quarter is forecast at $1.19. Next year's EPS is expected at $4.94. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 7 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $127.00 to $61.00. The high target offers 95.72% upside. The low target suggests -5.99% downside. The mean target is $84.62. This offers 30.41% upside. Lantheus Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -67.69%. The prior quarter beat by -4.27%. Over the last six quarters, Apple has recorded several small beats. These include -51.97% in July 31, 2024.

Shareholding & Insider Activity

Lantheus Holdings, Inc. has 67.99 million shares outstanding. The public float is 59.94 million shares, elevated short interest at 16.39% of float. This equals 8.42 million shares. The short ratio is 8.25 days. Institutional investors hold 119.95% of the float. Insiders own 2.24%. PATEL RAJIV A holds 3.48 million shares, FARALLON PARTNERS L L C/CA has 3.48 million shares and Heino Mary Anne has 318.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 6.82 million shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Lantheus generated $1.30B in revenue, or $18.46 per share. Gross margin was 54.73%, operating margin 28.13%, and net profit margin 25.20%. Returns are exceptional, with ROA at 19.78% and ROE at 40.04%.
On valuation metrics, Lantheus trades at a P/E of 25.80, P/S of 2.87 and P/B of 3.86. The current ratio is 2.67 and quick ratio is 2.49. Operationally, the company’s inventory turnover is 9.29 and cash conversion cycle is 88.98 days. Debt-to-equity is 0.55, supported by a cash flow-to-debt ratio of 0.74.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Lantheus posted revenue of $1.30B, down slightly from $935.06M in the prior quarter. Gross profit was $709.54M (margin 54.73%). Operating income was $364.64M (margin 28.1%). Net income was$326.66M (EPS $4.79).
The company ended the quarter with $713.66M in cash and short-term investments, a total debt of $616.95M, and net debt of - $96.71M. Total assets were $1.65B, with equity of $815.89M. Financials further reflected stability, with operating cash flow of $305.26M, free cash flow of $258.71M, and capital expenditures of - $46.56M.

Frequently Asked Questions

What is the current Lantheus Holdings, Inc. (LNTH) stock price?
Lantheus Holdings, Inc. (NASDAQ: LNTH) stock price is $64.89 in the last trading session. During the trading session, LNTH stock reached the peak price of $65.68 while $64.10 was the lowest point it dropped to. The percentage change in LNTH stock occurred in the recent session was 0.05% while the dollar amount for the price change in LNTH stock was $0.03.
LNTH's industry and sector of operation?
The NASDAQ listed LNTH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Lantheus Holdings, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of LNTH?
Mr. Mark Richard Kinarney
Senior Director of Investor Relations
Mr. Etienne Montagut
Chief Bus. Officer
Ms. Linda S. Lennox
Vice President of Corporation Communications & Chief of Staff
Melissa Downs
Director of Corporation Communications
Ms. Mary Anne Heino
Chief Executive Officer & Director
Mr. Paul M. Blanchfield
Pres
Mr. Robert J. Marshall Jr., CFA
Chief Financial Officer
Ms. Ying Yao
Chief HR Officer
Mr. Daniel M. Niedzwiecki
Chief Admin. Officer, Gen. Counsel & Corporation Sec.
Ms. Andrea Sabens
Chief Accounting Officer
Ms. Dorothy Barr
Senior Vice President of Manufacturing & Technical Operations
Ms. Carol Walker
Senior Vice President of Quality
How LNTH did perform over past 52-week?
LNTH's closing price is 37.33% higher than its 52-week low of $47.25 where as its distance from 52-week high of $111.29 is -41.69%.
How many employees does LNTH have?
Number of LNTH employees currently stands at 808.
Link for LNTH official website?
Official Website of LNTH is: https://www.lantheus.com
How do I contact LNTH?
LNTH could be contacted at phone 978 671 8001 and can also be accessed through its website. LNTH operates from 331 Treble Cove Road, Bedford, MA 01862, United States.
How many shares of LNTH are traded daily?
LNTH stock volume for the day was 826.03K shares. The average number of LNTH shares traded daily for last 3 months was 999.97K.
What is the market cap of LNTH currently?
The market value of LNTH currently stands at $4.41B with its latest stock price at $64.89 and 67.99M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph